TNXP: Raymond James Initiates
Raymond James analyst initiates coverage on Tonix Pharmaceuticals with a Strong Buy rating and a price target of $26
Top Wall Street analysts changed their outlook on these top names.
For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Goldman Sachs analyst James Schneider initiated coverage on Intel Corp (NASDAQ: INTC ) with a Neutral rating and announced a price target of $150.
Intel shares closed at $131.91 on Wednesday.
See how other analysts view this stock.
Keefe, Bruyette & Woods analyst Damon Delmonte initiated coverage on Arrow Financial Corp (NASDAQ: AROW ) with a Market Perform rating and announced a price target of $42.
Arrow Financial shares closed at $40.36 on Wednesday.
See how other analysts view this stock.
BTIG analyst Gregory Lewis initiated coverage on Boost Run Inc (NASDAQ: BRUN ) with a Buy rating and announced a price target of $45.
Boost Run shares closed at $34.26 on Wednesday.
See how other analysts view this stock.
Raymond James analyst Tiago Fauth initiated coverage on Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) with a Strong Buy rating and announced a price target of $26.
Tonix Pharmaceuticals shares closed at $12.10 on Wednesday.
See how other analysts view this stock.
Roth Capital analyst Max Masucci initiated coverage on Castle Biosciences Inc (NASDAQ: CSTL ) with a Buy rating and announced a price target of $40.
Castle Biosciences shares closed at $22.12 on Wednesday.
See how other analysts view this stock.
Considering buying TNXP stock? Here’s what analysts think: Photo via Shutterstock